Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 6/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 6/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.41 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.39 |
| ▸ | CDC25B | P30305 | 4/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25964180 | 0.94 | SSTR1 (0.39) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL22842844 | 0.94 | SSTR1 (0.39) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL25964134 | 0.94 | SSTR1 (0.39) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL31471789 | 0.89 | SSTR1 (0.48) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL8196174 | 0.85 | SSTR1 (0.43) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL19453278 | 0.84 | HPSE (0.35) | GJB2 | |
| SCHEMBL10608381 | 0.83 | SSTR1 (0.53) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL25964309 | 0.81 | LGALS3 (0.46) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL22842845 | 0.81 | SSTR4 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL22991832 | 0.79 | GJB2 (0.35) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248839-A1 | IMMUNOGENIC COMPOSITIONS | GSK VACCINES S.R.L. (IT) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248839-A1 | IMMUNOGENIC COMPOSITIONS | FCGR3B, B3GAT3, CD47 | SSTR1 3245/4885SSTR2 3170/4885SSTR4 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.